28 January 2016 - The U.S. FDA today approved Halaven (eribulin mesylate) for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm483714.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery